MedTrace Logo

Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics

NCT06948292 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 127

Last updated 2025-09-08

No results posted yet for this study

Summary

QRX-3, a new drug that stabilized the kidney renal tubular cell and increase the activity of NAD ( nicotinamide adenine dineuclotide )within the kidney cells; leading to decrease oxidative changes intracellularly, repair of renal tubular injury and restoration of optimized renal function above baseline , will be studied in patients with progressive chronic kidney disease over 12 months . The result of the change in renal function expressed as creatinine GFR (Glomerular filtration decline) over the treatment duration will be compared in the treatment group will be compared to control group without the medication during that same period .

Conditions

  • Chronic Kidney Disease Stages 3-5
  • Diabetic Kidney Disease
  • Hypertensive Kidney Disease

Interventions

DRUG

QRX-3

phase 2B CKD study

Sponsors & Collaborators

  • Ebima Clifford Okundaye

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2024-08-30
Completion
2024-10-30
FDA Drug
Yes

Countries

  • United States

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06948292 on ClinicalTrials.gov